DOI: 10.32364/2311-7729-2020-20-2-85-91
Association between instillation time of glaucoma eye drops
and their efficacy
A.M. Getmanova1, A.Yu. Brezhnev2, I.R. Gazizova3, A.V. Kuroyedov4,5, O.N. Onufriichuk6
1Bryansk Regional Hospital, Bryansk, Russian Federation
2Kursk State Medical University, Kursk, Russian Federation
3Institute of Experimental Medicine of the Russian Academy of Sciences, St. Petersburg, Russian Federation
4P.V. Mandryka Military Clinical Hospital, Moscow, Russian Federation
5Pirogov Russian National Research Medical University, Moscow, Russian Federation
6G.I. Turner National Medical Research Center for Children’s Orthopedics and Trauma Surgery, Pushkin, Russian Federation
Modern pharmacotherapy for glaucoma includes a wide range of intraocular pressure (IOP)-lowering medications of various groups. Yet, current set of medications cannot address a myriad of challenges in glaucoma treatment. Therefore, the search for novel pharmacotherapies for glaucoma is underway. IOP and the efficacy of topical IOP-lowering medications fluctuate throughout the day being volatile items. In the past decade, 24-hour IOP monitoring has provided novel data on 24-hour efficacy of many IOP-lowering medications. However, despite a large number and volume of studies, optimal instillation period of various glaucoma eye drops is still unclear. An interesting and promising area of modern pharmacotherapy is chronotherapy that implies target prescription of a drug in specific daytime considering circadian rhythms to achieve maximum effect. This paper reviews current modalities of personalized chronopharmacotherapy and their potential application in r outine glaucoma practice. This personalized approach will help achieve target IOP and improve glaucoma control.
Keywords: intraocular pressure, 24-hour monitoring, diurnal IOP fluctuations, glaucoma, pharmacotherapy, chronotherapy.
For citation: Getmanova A.M., Brezhnev A.Yu., Gazizova I.R. et al. Association between instillation time of glaucoma eye drops and their efficacy. Russian Journal of Clinical Ophthalmology. 2020;20(2):85–91. DOI: 10.32364/2311-7729-2020-20-2-85-91.
References
1. National guidelines in glaucoma for practitioners. M.: GEOTAR-Media; 2019 (in Russ.).
2. Ophthalmology: National guidelines. M.: GEOTAR-Media; 2018 (in Russ.).
3. Tanna A.P., Johnson M. Ophthalmology. 2018;125(11):1741–1756. DOI: 10.1016/j.ophtha.2018.04.040.
4. Petrov S.Y., Safonova D.M. Rho-kinase inhibitors — new topical hypotensive drugs in the glaucoma treatment. Natsional’nyi zhurnal glaukoma. 2014;13(4):92–100 (in Russ.).
5. Egorov E.A., Astakhov Yu.S., Erichev V.P. National glaucoma guidelines. M.: GEOTAR-Media. 2015 (in Russ.).
6. Wagh D.W. Chronobiology, Circadian Variations and Chronotherapy of Glaucoma. JChrDD. 2013;4(2–3):45–52.
7. Guskova T.A., Lieberman S.S. The importance of chronobiology for pharmacological and toxicological studies. Farmakologiya i toksikologiya. 1987;50(4):111–118 (in Russ.).
8. Maslennikov A.I. About diurnal fluctuation of intraocular pressure in glaucoma. Vestnik oftal’mologii. 1905;22(3):212–237 (in Russ.).
9. Ustinova E.I. Methods of early glaucoma diagnosis. Moscow: Medicine; 1966 (in Russ.).
10. Mansouri K., Weinreb R.N., Medeiros F.A. Is 24-hour intraocular pressure monitoring necessary in glaucoma? Semin Ophthalmol. 2013;28(3):157–164. DOI: 10.3109/08820538.2013.771201.
11. Kuroyedov A.V., Brezhnev A.Yu., Egorov E.A. et al. New characteristics of IOP level in primary open-angle glaucoma patients before and after surgery on the background of round-the-clock monitoring with the use of modern technology (pilot study). Russian Journal of Clinical Ophthalmology. 2016;2:65–74 (in Russ.). DOI: 10.21689/2311-7729-2016-16-2-65-74.
12. Brezhnev A.Yu., Baranov V.I., Kuroyedov A.V. et al. 24-hour intraocular pressure monitoring: opportunities and challenges. Natsional’nyi Zhurnal Glaukoma. 2018;17(3):77–85 (in Russ.). DOI: 10.25700/NJG.2018.03.09.
13. Brezhnev A.Yu. Hallmarks of medical treatment of pseudoexfoliative glaucoma. Russian Journal of Clinical Ophthalmology. 2016;4:220–223 (in Russ.). DOI: 10.21689/2311-7729-2016-16-4-220 223.
14. Kim J.H., Caprioli J. Intraocular Pressure Fluctuation: Is It Important? J Ophthalmic Vis Res. 2018;13(2):170–174. DOI: 10.4103/jovr.jovr_35_18.
15. Quaranta L., Katsanos A., Russo A., Riva I. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol. 2013;58(1):26–41. DOI: 10.1016/j.survophthal.2012.05.003.
16. Caprioli J., Coleman A.L. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115(7):1123–1129. DOI: 10.1016/j.ophtha.2007.10.031.
17. Asrani S., Zeimer R., Wilensky J. et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134–142. DOI: 10.1097/00061198-200004000-00002.
18. Matlach J., Bender S., König J. et al. Investigation of intraocular pressure fluctuation as a risk factor of glaucoma progression. Clin Ophthalmol. 2018;13:9–16. DOI: 10.2147/OPTH.S186526.
19. Stewart W.C., Konstas A.G., Nelson L.A. et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115:1117–1122. DOI: 10.1016/j.ophtha.2007.10.004.
20. Avdeev R.V., Alexandrov A.S., Bakunina N.A. et al. Comparison of primary open-angle glaucoma treatment regimens for patients with disease progression characteristics. Part 2. The efficacy of initial hypotensive treatment regimens. Natsional’nyi zhurnal glaukoma. 2018;17(2):65–83 (in Russ.).
21. Gazizova I., Avdeev R., Aleksandrov A. et al. Multicenter study of intraocular pressure level in patients mith moderate and advanced primary open-angle glaucoma on treatment. Invest Ophthalmol Vis Sci. 2016;57(12):6470. DOI: 10.17816/OV2015143-60.
22. Garway-Heath D.F., Crabb D.P., Bunce C. et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebocontrolled trial. Lancet. 2015;385:1295–1304. DOI: 10.1016/S01406736(14)62111-5.
23. Astakhov Yu.S., Nechiporenko P.A. Prostaglandin analogues: past, present, and future. Oftal`mologicheskie vedomosti. 2017;10(1):40–52 (in Russ.). DOI: 10.17816/OV10140-52.
24. Konstas А., Quaranta L., Bozkurt B. et al. 24-h Efficacy of Glaucoma Treatment Options. Adv Ther. 2016;33:481–517. DOI:10.1007/s12325–016–0302–0.
25. Konstas A.G., Mikropoulos D., Kaltsos К. et al. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology. 2006;113(3):446–500. DOI: 10.1016/j.ophtha.2005.10.053.
26. Ford B.A, Gooi M., Carlsson A., Crichton A.C. Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing. J Glaucoma. 2013;22(1):1–4. DOI: 10.1097/IJG.0b013e31822e622f.
27. Riva I., Katsanos A., Floriani I. et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014;23(8):535–540. DOI: 10.1097/IJG.0000000000000073.
28. Kahook M.Y., Noecker R.J. Evaluation of adherence to morning versus evening glaucoma medication dosing regimens. Clin Ophthalmol. 2007;1(1):79–83.
29. Kiseleva O.A., Bessmertny A.M., Yakubova L.V. et al. Efficiency and safety of the drug Travapress in patients with primary open-angle glaucoma. Vestnik oftal’mologii. 2019;135(1):67–73 (in Russ.). DOI: 10.17116/oftalma201913501167.
30. Lee P.W., Doyle A., Stewart J.A. et al. Metaanalysis of timolol on diurnal and nighttime intraocular pressure and blood pressure. Eur J Ophthalmol. 2010;20(6):1035–1041. DOI: org/10.1177/112067211002000602.
31. Quaranta L., Katsanos A., Floriani I. et al. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52(10):1552–1557. DOI: 10.1177/0091270011420254.
32. Higginbotham E.J., Olander K.W., Kim E.E. et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension. Arch Ophthalmol. 2010;28(2):165–172. DOI: 10.1001/archophthalmol.2009.384.
33. Diestelhorst M., Larsson L.I., European Latanoprost Fixed Combination Study Group A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004;88(2):199–203. DOI: 10.1136/bjo.2003.018234.
34. Diestelhorst M., Larsson L.I. European-Canadian Latanoprost Fixed Combination Study Group A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113(1):70–76. DOI: 10.1016/j.ophtha.2005.06.027.
35. Lovpache D.N. An experience of using the fixed combination Duoprost (Rompharm) in patients with advanced primary open angle glaucoma. Rossiyskiy oftal’mologicheskiy zhurnal. 2015;9(2):83–87 (in Russ.).
36. Konstas A.G., Holló G., Mikropoulos D. et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010;94(2):209–213. DOI: 10.1136/bjo.2008.155317.
37. Hommer A. Ganfort Investigators Group I A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17(1):53–62. DOI: 10.1177/112067210701700436.
38. Schuman J.S., Katz G.J., Lewis R.A. et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140(2):242–250. DOI: 10.1016/j.ajo.2005.02.058.
39. Hughes B.A., Bacharach J., Craven E.R. et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392–399. DOI: 10.1097/01.ijg.0000176935.08392.14.
40. Quaranta L., Biagioli E., Riva I. et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: A systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29(4):382–389. DOI: 10.1089/jop.2012.0186.
41. Nagornova Z.M., Kuroyedov A.V., Seleznev A.V. Comparative analysis of the efficacy and safety of fixed-dose combinations versus their individual components for open-angle glaucoma. Russian Journal of Clinical Ophthalmology. 2019;19(1):13–19 (in Russ.). DOI: 10.21689/2311-7729-2019-19-1-13-19.
42. Konstas A.G., Katsanos A., Athanasopoulos G.P. et al. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. Exp Opin Pharm. 2018;19(18):1981–1988. DOI: 10.1080/14656566.2018.1534958.
2. Ophthalmology: National guidelines. M.: GEOTAR-Media; 2018 (in Russ.).
3. Tanna A.P., Johnson M. Ophthalmology. 2018;125(11):1741–1756. DOI: 10.1016/j.ophtha.2018.04.040.
4. Petrov S.Y., Safonova D.M. Rho-kinase inhibitors — new topical hypotensive drugs in the glaucoma treatment. Natsional’nyi zhurnal glaukoma. 2014;13(4):92–100 (in Russ.).
5. Egorov E.A., Astakhov Yu.S., Erichev V.P. National glaucoma guidelines. M.: GEOTAR-Media. 2015 (in Russ.).
6. Wagh D.W. Chronobiology, Circadian Variations and Chronotherapy of Glaucoma. JChrDD. 2013;4(2–3):45–52.
7. Guskova T.A., Lieberman S.S. The importance of chronobiology for pharmacological and toxicological studies. Farmakologiya i toksikologiya. 1987;50(4):111–118 (in Russ.).
8. Maslennikov A.I. About diurnal fluctuation of intraocular pressure in glaucoma. Vestnik oftal’mologii. 1905;22(3):212–237 (in Russ.).
9. Ustinova E.I. Methods of early glaucoma diagnosis. Moscow: Medicine; 1966 (in Russ.).
10. Mansouri K., Weinreb R.N., Medeiros F.A. Is 24-hour intraocular pressure monitoring necessary in glaucoma? Semin Ophthalmol. 2013;28(3):157–164. DOI: 10.3109/08820538.2013.771201.
11. Kuroyedov A.V., Brezhnev A.Yu., Egorov E.A. et al. New characteristics of IOP level in primary open-angle glaucoma patients before and after surgery on the background of round-the-clock monitoring with the use of modern technology (pilot study). Russian Journal of Clinical Ophthalmology. 2016;2:65–74 (in Russ.). DOI: 10.21689/2311-7729-2016-16-2-65-74.
12. Brezhnev A.Yu., Baranov V.I., Kuroyedov A.V. et al. 24-hour intraocular pressure monitoring: opportunities and challenges. Natsional’nyi Zhurnal Glaukoma. 2018;17(3):77–85 (in Russ.). DOI: 10.25700/NJG.2018.03.09.
13. Brezhnev A.Yu. Hallmarks of medical treatment of pseudoexfoliative glaucoma. Russian Journal of Clinical Ophthalmology. 2016;4:220–223 (in Russ.). DOI: 10.21689/2311-7729-2016-16-4-220 223.
14. Kim J.H., Caprioli J. Intraocular Pressure Fluctuation: Is It Important? J Ophthalmic Vis Res. 2018;13(2):170–174. DOI: 10.4103/jovr.jovr_35_18.
15. Quaranta L., Katsanos A., Russo A., Riva I. 24-hour intraocular pressure and ocular perfusion pressure in glaucoma. Surv Ophthalmol. 2013;58(1):26–41. DOI: 10.1016/j.survophthal.2012.05.003.
16. Caprioli J., Coleman A.L. Intraocular pressure fluctuation a risk factor for visual field progression at low intraocular pressures in the advanced glaucoma intervention study. Ophthalmology. 2008;115(7):1123–1129. DOI: 10.1016/j.ophtha.2007.10.031.
17. Asrani S., Zeimer R., Wilensky J. et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9(2):134–142. DOI: 10.1097/00061198-200004000-00002.
18. Matlach J., Bender S., König J. et al. Investigation of intraocular pressure fluctuation as a risk factor of glaucoma progression. Clin Ophthalmol. 2018;13:9–16. DOI: 10.2147/OPTH.S186526.
19. Stewart W.C., Konstas A.G., Nelson L.A. et al. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008;115:1117–1122. DOI: 10.1016/j.ophtha.2007.10.004.
20. Avdeev R.V., Alexandrov A.S., Bakunina N.A. et al. Comparison of primary open-angle glaucoma treatment regimens for patients with disease progression characteristics. Part 2. The efficacy of initial hypotensive treatment regimens. Natsional’nyi zhurnal glaukoma. 2018;17(2):65–83 (in Russ.).
21. Gazizova I., Avdeev R., Aleksandrov A. et al. Multicenter study of intraocular pressure level in patients mith moderate and advanced primary open-angle glaucoma on treatment. Invest Ophthalmol Vis Sci. 2016;57(12):6470. DOI: 10.17816/OV2015143-60.
22. Garway-Heath D.F., Crabb D.P., Bunce C. et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebocontrolled trial. Lancet. 2015;385:1295–1304. DOI: 10.1016/S01406736(14)62111-5.
23. Astakhov Yu.S., Nechiporenko P.A. Prostaglandin analogues: past, present, and future. Oftal`mologicheskie vedomosti. 2017;10(1):40–52 (in Russ.). DOI: 10.17816/OV10140-52.
24. Konstas А., Quaranta L., Bozkurt B. et al. 24-h Efficacy of Glaucoma Treatment Options. Adv Ther. 2016;33:481–517. DOI:10.1007/s12325–016–0302–0.
25. Konstas A.G., Mikropoulos D., Kaltsos К. et al. 24-hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology. 2006;113(3):446–500. DOI: 10.1016/j.ophtha.2005.10.053.
26. Ford B.A, Gooi M., Carlsson A., Crichton A.C. Morning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosing. J Glaucoma. 2013;22(1):1–4. DOI: 10.1097/IJG.0b013e31822e622f.
27. Riva I., Katsanos A., Floriani I. et al. Long-term 24-hour intraocular pressure control with travoprost monotherapy in patients with primary open-angle glaucoma. J Glaucoma. 2014;23(8):535–540. DOI: 10.1097/IJG.0000000000000073.
28. Kahook M.Y., Noecker R.J. Evaluation of adherence to morning versus evening glaucoma medication dosing regimens. Clin Ophthalmol. 2007;1(1):79–83.
29. Kiseleva O.A., Bessmertny A.M., Yakubova L.V. et al. Efficiency and safety of the drug Travapress in patients with primary open-angle glaucoma. Vestnik oftal’mologii. 2019;135(1):67–73 (in Russ.). DOI: 10.17116/oftalma201913501167.
30. Lee P.W., Doyle A., Stewart J.A. et al. Metaanalysis of timolol on diurnal and nighttime intraocular pressure and blood pressure. Eur J Ophthalmol. 2010;20(6):1035–1041. DOI: org/10.1177/112067211002000602.
31. Quaranta L., Katsanos A., Floriani I. et al. Circadian intraocular pressure and blood pressure reduction with timolol 0.5% solution and timogel 0.1% in patients with primary open-angle glaucoma. J Clin Pharmacol. 2012;52(10):1552–1557. DOI: 10.1177/0091270011420254.
32. Higginbotham E.J., Olander K.W., Kim E.E. et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension. Arch Ophthalmol. 2010;28(2):165–172. DOI: 10.1001/archophthalmol.2009.384.
33. Diestelhorst M., Larsson L.I., European Latanoprost Fixed Combination Study Group A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension. Br J Ophthalmol. 2004;88(2):199–203. DOI: 10.1136/bjo.2003.018234.
34. Diestelhorst M., Larsson L.I. European-Canadian Latanoprost Fixed Combination Study Group A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components. Ophthalmology. 2006;113(1):70–76. DOI: 10.1016/j.ophtha.2005.06.027.
35. Lovpache D.N. An experience of using the fixed combination Duoprost (Rompharm) in patients with advanced primary open angle glaucoma. Rossiyskiy oftal’mologicheskiy zhurnal. 2015;9(2):83–87 (in Russ.).
36. Konstas A.G., Holló G., Mikropoulos D. et al. Twenty-four-hour intraocular pressure control with bimatoprost and the bimatoprost/timolol fixed combination administered in the morning, or evening in exfoliative glaucoma. Br J Ophthalmol. 2010;94(2):209–213. DOI: 10.1136/bjo.2008.155317.
37. Hommer A. Ganfort Investigators Group I A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur J Ophthalmol. 2007;17(1):53–62. DOI: 10.1177/112067210701700436.
38. Schuman J.S., Katz G.J., Lewis R.A. et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140(2):242–250. DOI: 10.1016/j.ajo.2005.02.058.
39. Hughes B.A., Bacharach J., Craven E.R. et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392–399. DOI: 10.1097/01.ijg.0000176935.08392.14.
40. Quaranta L., Biagioli E., Riva I. et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: A systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013;29(4):382–389. DOI: 10.1089/jop.2012.0186.
41. Nagornova Z.M., Kuroyedov A.V., Seleznev A.V. Comparative analysis of the efficacy and safety of fixed-dose combinations versus their individual components for open-angle glaucoma. Russian Journal of Clinical Ophthalmology. 2019;19(1):13–19 (in Russ.). DOI: 10.21689/2311-7729-2019-19-1-13-19.
42. Konstas A.G., Katsanos A., Athanasopoulos G.P. et al. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. Exp Opin Pharm. 2018;19(18):1981–1988. DOI: 10.1080/14656566.2018.1534958.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
Previous article
Next article
